The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Rosenberg Martin since 2008.
The trader's CIK number is 1320122.
At the time of the last reporting, Rosenberg Martin was the Director of Cubist Pharmaceuticals Inc. (stock ticker symbol CBST).
Also see all insider trading activities at Cubist Pharmaceuticals Inc.
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2013 | CBST | 0 | $0 | 15,472 | $1,005,680 | 16,819 | $368,388 |
2012 | CBST | 0 | $0 | 40,000 | $1,684,660 | 40,000 | $650,550 |
2011 | CBST | 0 | $0 | 11,500 | $426,661 | 11,500 | $209,530 |
2009 | CBST | 0 | $0 | 0 | $0 | 2,000 | $19,120 |
2008 | CBST | 0 | $0 | 10,000 | $220,000 | 10,000 | $100,200 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2013-09-09 | CBST | Option Ex | 15,472 | 23.81 | 368,388 |
2013-09-09 | CBST | Sale | 15,472 | 65.00 | 1,005,680 |
2013-06-06 | CBST | Option Ex | 1,347 | .00 | 0 |
2012-10-01 | CBST | Option Ex | 10,000 | 22.71 | 227,100 |
2012-10-01 | CBST | Sale | 10,000 | 47.75 | 477,480 |
2012-07-02 | CBST | Sale | 10,000 | 37.88 | 378,760 |
2012-07-02 | CBST | Option Ex | 10,000 | 22.30 | 222,950 |
2012-04-02 | CBST | Option Ex | 10,000 | .00 | 0 |
2012-04-02 | CBST | Sale | 10,000 | 42.76 | 427,600 |
2012-01-03 | CBST | Option Ex | 10,000 | 20.05 | 200,500 |
2012-01-03 | CBST | Sale | 10,000 | 40.08 | 400,820 |
2011-12-15 | CBST | Option Ex | 11,500 | 18.22 | 209,530 |
2011-12-15 | CBST | Sale | 11,500 | 37.10 | 426,661 |
2009-03-30 | CBST | Option Ex | 2,000 | 9.56 | 19,120 |
2008-07-22 | CBST | Sale | 10,000 | 22.00 | 220,000 |
2008-07-22 | CBST | Option Ex | 10,000 | 10.02 | 100,200 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Rosenberg Martin (Director of Cubist Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.